



Study Synopsis

Tertiary Cytoreductive Surgery in Recurrent Epithelial Ovarian Cancer

Protocol title	Tertiary Cytoreductive Surgery in Recurrent Epithelial Ovarian Cancer.
Study format	Multicenter, retrospective.
Principal Investigator	Prof. Stefano Greggi, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy.
Eligibility	Patients with a second relapse of epithelial ovarian cancer (including tubal and peritoneal epithelial cancers) undergoing elective tertiary cytoreductive surgery (TCS) during the period 2005 – 2015.
Objectives	<ul style="list-style-type: none"> - To evaluate the impact of TCS on survival; - To determine predictors of complete TCS; - To formulate a hypothesis for selection criteria/predictive factors for successful complete TCS (such hypothesis is intended to form the basis for a subsequently planned prospective trial evaluating a predictive model for complete TCS in recurrent epithelial ovarian cancer).
Inclusion criteria	<ul style="list-style-type: none"> - Performance status according to ECOG 0 – 1; - Treatment-free interval (TFI) \geq6 months after completion of first-/second-line therapy.
Exclusion criteria	<ul style="list-style-type: none"> - Patients operated on for strictly palliative purposes; - performance status according to ECOG $>$1; - serological recurrence only (CA125 serum levels $>$35 UI/mL); - non-epithelial or borderline tumors; - TFI $<$6 months after completion of first-/second-line therapy; - patients with second malignancies who had been treated by laparotomy or who had a therapy that could interfere with the treatment of relapsed ovarian cancer.
Sample size	10 patients (per participating Centre)
Duration of study	24 months (including data processing) COMPLETED/DATA ANALYSIS